← back to problem page
Whitepaper · v0.1·x-risk frontier·open to refutation

An optimism.fun request for startups

Biosecurity & pandemic preparedness

Stop the next pandemic, natural or engineered, before it spreads.

Published

2026-04-24

Authors

optimism.fun

Status

Draft · v0.1

License

CC BY 4.0

§0weekly drop · week 1

Editor’s drop

Published 2026-08-20 · optimism.fun

blackpaper · the problem

COVID-19 killed an estimated 20 million people (WHO/Our World in Data excess-mortality reconstruction) and cost the global economy an estimated $13.8 trillion in cumulative output through 2024, per the IMF. That was a naturally emerging pathogen with a fatality rate under 1%. The next one does not have to be natural, and does not have to be that mild. Gain-of-function research, commercial DNA synthesis, and AI-assisted protein design have converged on a genuinely dangerous point: benchtop DNA synthesizers are on a trajectory to print virus-length genetic sequences within roughly two to five years (Arms Control Association, Nov 2025), largely outside any screening regime. Researchers have already demonstrated that fragments of the 1918 influenza virus and ricin toxin can be ordered by splitting requests across synthesis vendors and disguising the sequence, defeating today's screening. The Biological Weapons Convention has no operational rules for benchtop synthesis or AI-designed pathogens. In the US, a 2026 executive order let the prior DNA-synthesis screening framework lapse without a replacement before its own deadline. Meanwhile the detection side is worse than the containment side. The world currently finds novel pathogens by counting hospitalizations, meaning a fast-spreading engineered pathogen with a multi-week incubation period could infect a meaningful fraction of the planet before anyone official notices a pattern. Wastewater and air metagenomic sequencing, the only approach that could plausibly catch a novel pathogen agnostic of what it is, currently covers a token fraction of the world's population. The financing gap is quantified, not vague. A G20 Joint Finance and Health Task Force panel put the additional international financing needed for a fit-for-purpose pandemic-prevention architecture (surveillance, health systems, vaccine manufacturing capacity, governance) at $10.5 billion a year, concentrated in low- and lower-middle-income countries. An earlier G20 High-Level Independent Panel (2021) put the number at $15 billion a year. Neither figure has been close to fully funded; the Pandemic Fund, the closest thing to an implementing vehicle, has raised roughly $2 billion in pledges since 2022, against a stated multi-year need in the tens of billions. The honest tail-risk framing: this is not a welfare problem, it is closer to a civilizational one. 80,000 Hours rates catastrophic pandemic prevention a top-tier cause on exactly this basis: an event is plausible within a working lifetime that kills not 20 million but hundreds of millions to billions, and the marginal dollar toward early-warning infrastructure and rapid-response manufacturing is unusually high-leverage because so little of that infrastructure exists yet. What is true today, without hedging: the last pandemic killed 20 million people and cost the world $13.8 trillion. The tools to make an engineered one deliberately worse than that are getting cheaper and more accessible every year. The tools to detect one early and manufacture a countermeasure in weeks instead of a year exist in prototype but not at scale. And the funding gap to close that, by the G20's own accounting, is $10.5 billion a year, which the world has not paid.

whitepaper · the proposal

What would actually have to get built: 1. A pathogen-agnostic early-warning layer: metagenomic sequencing of wastewater and air samples, run continuously across population centers, flagging anomalous genetic signal before hospitalizations show a pattern. This is not speculative; the Nucleic Acid Observatory and CDC's wastewater surveillance programs already run pilots at this. 2. Mandatory, closed-loop DNA synthesis screening: every commercial and benchtop synthesizer checks every order against a hazard database before printing, with no order-splitting workaround. Companies like Twist Bioscience already screen; the gap is coverage of benchtop devices and enforcement teeth. 3. A rapid-response manufacturing base: platform vaccine technology (mRNA and successors) that can go from a pathogen's genetic sequence to a deployable vaccine in under 100 days (CEPI's 100 Days Mission), plus the actual distributed manufacturing capacity, not just the platform, to hit that target globally rather than in one country first. Why now: mRNA platforms proved themselves at civilizational scale during COVID, going from sequence to a deployed vaccine in under a year for the first time in history, and the manufacturing cost curve has kept falling since. Metagenomic sequencing costs have fallen with the same cost curves that drove the genomics revolution generally; a NovaSeq run now costs roughly $4,000 at scale (core-facility pricing), down an order of magnitude from a decade ago. None of the three components above require a scientific breakthrough. They require money, coordination, and deployment, a fundamentally different, faster kind of problem than waiting on the science. The math on what this is worth: Start with the detection layer, because it is the most concretely costed piece. Published National Wastewater Surveillance System program costs imply roughly $168,000 per year to run metagenomic sequencing coverage for a catchment of 500,000 people (five sites for $840,000/year). Scale that to the roughly 4.5 billion people living in the world's urban areas (UN Population Division puts global urbanization at about 56% of 8.1 billion people), and you need about 9,000 sites. At $168,000 per site per year, that is a $1.5 billion-a-year detection network: global, continuous, pathogen-agnostic. That is a real, bottom-up, buildable number, not a guess, and it is small relative to the stakes: about 0.01% of the $13.8 trillion the last pandemic cost. The bigger number is the one the G20's own task force already published: $10.5 billion a year in additional international financing to fund the complete pandemic-prevention architecture (surveillance plus health-system strengthening plus vaccine manufacturing capacity plus governance), concentrated where the gaps are worst (G20 Joint Finance and Health Task Force, reported via Center for Global Development and OECD). That is this problem's realistic global solution price tag: on the order of $10 billion a year, which is a fraction of Pfizer's single-year 2021 revenue from COVID vaccines alone, and a rounding error against the $13.8 trillion the world already paid for not having it. Who backs this: part of it is a startup opportunity (biosecurity-as-a-service, DNA-synthesis-screening SaaS, wastewater sequencing-as-a-service contracts with municipal water utilities), and part of it is not fundable by markets at all, because the payoff is a tail event that may never land inside any single investor's holding period, which is exactly the shape of thing philanthropic and sovereign capital (Open Philanthropy, CEPI, national pandemic-preparedness budgets) exists to fund. The realistic split: the detection and screening layers ($1.5-3 billion/year) are plausibly a for-profit, recurring-revenue business sold to governments and water utilities. The manufacturing-capacity buildout and the poorest-country financing gap, the bulk of the $10.5 billion, is closer to a Gavi/CEPI-style blended-capital problem. Confidence: the $1.5 billion detection-network figure is a solid bottom-up estimate from real per-site costs, but assumes coverage economics hold at roughly 18x the currently piloted scale, which is untested, so call it medium confidence. The $10.5 billion/year macro figure is the G20's own published number and is the more defensible headline, though panels have disagreed by 30-50% on the exact figure ($10.5B vs $15B vs a broader ~$31B "full response" estimate elsewhere in the literature), so treat it as an order of magnitude, not a precise budget line.
§1abstract

The four-axis ranking

We rank humanity’s most important problems on four quantifiable dimensions — quantity of humans affected, severity per person, current solution quality, and addressable market size — and package each as a proposal in the spirit of Musk’s Hyperloop Alpha. This document is the proposal for biosecurity & pandemic preparedness. Every number below is sourced and tagged with confidence. Every ranking is a conjecture, open to refutation.

Quantity · humans affected

8.1B

high

Severity · 0–1

1.00

low

Current solutions

3.0 / 10

med

Market size · TAM

$100.0B

low
§2problem statement

What we are trying to solve

COVID-19 demonstrated the tail risk from a single pathogen. Dual-use gene synthesis, lab leaks, and deliberate misuse mean that worst-case pandemics could be civilization-ending. Tractable: far-UVC sterilization, early-warning surveillance, broad-spectrum countermeasures, pathogen-agnostic detection.

§3why it persists

The gap between the world and the world that is physically possible

Today: World detects novel pathogens months after they spread; vaccines take 12+ months to develop and longer to globally distribute.

Current solution quality is rated 3.0 / 10 (med confidence) — meaning there is substantial unclaimed ground between what exists and what is possible. estimated — decent reactive vaccines but pathogen-agnostic detection + rapid global distribution still weak.

§4existing alternatives

Who is already working on this

4 entities are currently working on this problem across public markets, private companies, and research orgs. Each is evidence the market is real; none has obviously solved it.

Moderna

public · USA

mRNA platform company. Pandemic preparedness via rapid vaccine development, plus pipeline in malaria, HIV, and rare disease.

$10.5B

Ginkgo Bioworks

public · USA

Cell programming platform. Biosecurity Division runs metagenomic surveillance and pathogen detection at scale.

$350M

Colossal Biosciences

private · USA

De-extinction and genetic engineering. Biosecurity adjacency via rapid genome editing and cold-chain logistics.

$10.2B

§5proposed direction

If we solve this, here is the world we get

After · 10 years

Pathogens detected within days via genomic surveillance; vaccines designed and manufactured in weeks; equitable global distribution. No mass-casualty pandemic events possible.

Requests for startups · 3 concrete companies to build

Pathogen-agnostic early warning

We detect outbreaks by waiting for humans to get sick and show up at hospitals — weeks late, by design. Build the metagenomic sampling network that flags any novel replicating pathogen in days.

why now
Sequencing cost fell below the threshold where continuous environmental metagenomics is economically routine.
shape
A network of wastewater, airport, and air-handler samplers feeding a continuous metagenomic pipeline that alarms on any novel exponentially-growing genome — known or unknown.
success
Time-to-detection for a novel pathogen drops from weeks to days, globally, before the first hospital wave.

Days-not-months vaccine manufacturing

mRNA proved the design step can take hours. Manufacturing, fill-finish, and distribution still take a year. Build the distributed, rapidly-reconfigurable biomanufacturing stack that closes the gap.

why now
Cell-free and benchtop synthesis matured; the constraint is now industrialization, not science.
shape
Containerized, standardized micro-factories + a regulatory playbook that lets a validated process move from sequence to vialed doses in days, near the point of need.
success
A new vaccine reaches a billion arms within weeks of pathogen identification, not within years.

Far-UVC as building infrastructure

We treat indoor airborne transmission as a fact of life. It is not — it is an untreated utility. Build the far-UVC + ventilation retrofit company that makes indoor air as safe as treated water.

why now
Far-UVC safety data matured and 222nm excimer cost is on a manufacturing learning curve.
shape
A retrofit + new-build company that designs, installs, and certifies far-UVC + ventilation for schools, transit, and offices, sold on insurance and absenteeism economics.
success
Airborne transmission indoors becomes as rare as cholera from tap water in developed economies.

full rubric + framing on the Requests for Startups page.

§6cost & scale

What the market can pay

The world is already paying $100.0B per year against this problem (projected global biosecurity + pandemic-prep market (vaccines, surveillance, broad-spectrum countermeasures, PPE) at full deployment; low confidence).

A successful solution does not need to capture more — it needs to redirect a meaningful slice of existing spend, plus the latent willingness-to-pay implied by the severity score above. The cost ceiling for a real solution is bounded by this number; everything cheaper is dominated, everything more expensive is a non-starter.

§7safety & considerations

What could go wrong, and how we know we are not wrong

Section in progress

Failure modes, ethical considerations, and the conditions under which this whitepaper would be falsified are being authored as the weekly cadence ships. The Deutschian commitment: every claim above is a conjecture; we publish the conditions under which we would update. Unpublished sections stay empty. A Monday newsletter is not promised. Subscribe to get the upgrade, or contribute on GitHub.

§8suggested investors

Who would back this

Capital allocators with a stated thesis or deployed portfolio in this domain. This is a starting list — Exa Websets enrichment will expand it to direct check-writers per company.

Venture Capital

Founders Fund

Contrarian hard tech that rebuilds the industrial base.

Venture Capital

a16z American Dynamism

National-interest technology, aerospace, defense, manufacturing, public safety.

Venture Capital

Lux Capital

Counter-conventional science at the edges of physics and biology.

§9voices

What the thinkers say

“Funded Fast Grants during COVID to demonstrate that biomedical research can move at wartime speed when the structure allows it.”

— Patrick Collison · Co-founder & CEO, Stripe

“Bio-manufacturing and biosecurity are named hard-quest categories in the Founders Fund thesis and deserve high-agency builders.”

— Trae Stephens · Partner & Co-founder
§10sources & criticism invite

Where this is wrong, tell us

Every number on this page carries a source and a confidence tag. Every section open to refutation. If a citation is wrong, a number is stale, or a conjecture is unfounded — file a correction.

corrections → use the feedback widget in the nav · open issue at github.com/adamtpang/optimism.fun

Published whitepapers

One problem.Published essays, not a Monday promise.

The essays that exist are listed at /whitepapers. A new essay is not promised every Monday. Weeks with no essay are empty on purpose. Nothing here invents a back catalog.

optimism.fun uses your email address only to send low-volume project updates through Resend. You can unsubscribe with one click at any time; read the privacy policy.